Drug intelligence / Profile preview

FNP 150

Development stage: Unknown
Lead developer: Ferrer
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

FNP 150 is an investigational inhaled therapy being developed for the acute treatment of "OFF" episodes in patients with Parkinson's disease. It utilizes the proprietary Staccato One Breath Technology, a delivery platform that converts a small molecule drug into a thermal aerosol for deep lung inhalation. This method allows for rapid systemic absorption and quick onset of action, mimicking the pharmacokinetic profile of an intravenous injection. Originally developed by Alexza Pharmaceuticals (a subsidiary of Ferrer), the rights to the Staccato platform and its pipeline, including FNP 150, were acquired by Lee's Pharmaceutical Holdings in December 2025.

Other names: Staccato Parkinson's

Targets

DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on FNP 150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FNP 150.

Explore the full profile